0
Chest Infections |

Effectiveness of Daily Versus Thrice Weekly Antituberculous Therapy in Patients With Tuberculous Meningitis

Nayan Desai*, MD; Nagesh Waghmare, MD; Dilip Karnad, MD
Author and Funding Information

King Edward Memorial Hospital and Seth G. S. Medical College, Mumbai, India


Chest. 2012;142(4_MeetingAbstracts):141A. doi:10.1378/chest.1390768
Text Size: A A A
Published online

Abstract

SESSION TYPE: TB and NTM

PRESENTED ON: Sunday, October 21, 2012 at 01:15 PM - 02:45 PM

PURPOSE: Tuberculous meningitis (TBM) kills or disables more than half of those affected with disease. Studies have shown that intermittent thrice weekly antituberculous therapy (ATT) is as effective as daily treatment. Directly Observed Treatment Short Course (DOTS) has been widely proposed by the World Health Organization (WHO) as the best way to treat tuberculosis. Whether thrice weekly therapy is as effective as daily therapy in patients with central nervous system (CNS) tuberculosis, especially TBM, is not known. Our aim was to compare the effect of thrice weekly ATT as used in the DOTS regimen with daily ATT in patients with TBM.

METHODS: Subjects within ages 12-75 years, with a diagnosis of TBM who were ATT-naive were enrolled in the study. Subjects with human immunodeficiency virus (HIV) infection, and pregnant women were excluded from the study. Out of 98 subjects assessed for eligibility, 71 subjects met the criteria, and were randomized to receive thrice weekly (36) versus daily (35) ATT. Both groups were followed-up for 9 months with 11 visits. Clinical features, Medical Research Council (MRC) scale for muscle strength, Rankin functional assessment scale, and complications of ATT were recorded at each visit. The primary endpoint of the study was Rankin functional scale score at 9 months. Five subjects were excluded from final analysis as they had not completed 9 months of follow-up.

RESULTS: Baseline characteristics of both the groups [35 in daily group and 36 intermittent group] were similar, except for higher percentage of seizures in the daily group. Patients in the daily ATT group had lower Rankin functional scale score (p = 0.037), lower Medical Research Council scale for muscle strength (p = 0.007), and lower incidence of new onset hydrocephalus (p = 0.03) at the end of 9 months compared to patients in the intermittent ATT group. There was no increase in ATT-related treatment complications in the daily group when compared to the intermittent group.

CONCLUSIONS: Daily therapy with antituberculous agents via DOTS strategy decreases the morbidity, and complications of disease in patients with TBM when compared to thrice weekly therapy.

CLINICAL IMPLICATIONS: Patients with TBM if treated with daily ATT have better outcomes as compared to thrice weekly group, without any mortality benefit. A larger randomized controlled trial is needed to support our hypothesis..

DISCLOSURE: The following authors have nothing to disclose: Nayan Desai, Nagesh Waghmare, Dilip Karnad

No Product/Research Disclosure Information

King Edward Memorial Hospital and Seth G. S. Medical College, Mumbai, India

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543